<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: The use of combination antiretroviral therapy (cART) has become a standard of care in the treatment of HIV infection. However, antiretroviral drug resistance occurs in a substantial number of patients. In resource-limited settings, genotypic resistance assay using a commercial kit is costly.Objective: Focus on the validation of an in-house HIV-1 specific genotypic drug resistance assay in Thai patients failing cART.Materials and methods: Results of HIV-1 genotypic drug resistance assay was evaluated by comparing an inhouse method to a commercial test. The TRUGENE HIV-1 genotyping kit was used in 79 plasma specimens (49 from HIV patients failing cART therapy and 30 from proficiency testing panels).Results: The results from the in-house assay were comparable to those obtained from the TRUGENE HIV-1 genotyping kit with >99.0% codon-to-codon agreement. The lower limit of detection by the in-house assay was approximately 100 copies/mL of HIV-1 RNA. In addition, this in-house assay would allow testing of samples from patients infected with HIV-1 subtype other than B.Conclusion: The in-house HIV-1 genotypic drug resistance assay may be used as an alternative to commercial kits, particularly in resource limited settings.</abstract>

Background: The use of combination antiretroviral therapy (cART) has become a standard of care in the treatment of HIV infection. However, antiretroviral drug resistance occurs in a substantial number of patients. In resource-limited settings, genotypic resistance assay using a commercial kit is costly.Objective: Focus on the validation of an in-house HIV-1 specific genotypic drug resistance assay in Thai patients failing cART.Materials and methods: Results of HIV-1 genotypic drug resistance assay was evaluated by comparing an inhouse method to a commercial test. The TRUGENE HIV-1 genotyping kit was used in 79 plasma specimens (49 from HIV patients failing cART therapy and 30 from proficiency testing panels).Results: The results from the in-house assay were comparable to those obtained from the TRUGENE HIV-1 genotyping kit with >99.0% codon-to-codon agreement. The lower limit of detection by the in-house assay was approximately 100 copies/mL of HIV-1 RNA. In addition, this in-house assay would allow testing of samples from patients infected with HIV-1 subtype other than B.Conclusion: The in-house HIV-1 genotypic drug resistance assay may be used as an alternative to commercial kits, particularly in resource limited settings.

Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit

Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand

Department of Medicine, Faculty of Medicine; Chiang Mai University, Chiang Mai 50200,

Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200,

Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200,

Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200,

Correspondence to: Department of Medicine, Faculty of Medicine Chiang Mai University, Chiang Mai 50200, Thailand

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Background: The use of combination antiretroviral therapy (cART) has become a standard of care in the treatment of HIV infection. However, antiretroviral drug...

Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit

Article Category: Original article

Publicado en línea: 04 feb 2017

Páginas: 249 - 255

DOI: https://doi.org/10.5372/1905-7415.0502.032

Palabras clave
Antiviral therapy, drug resistance, genotype, HIV-1, in-house assay

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit

Article Category: Original article

Publicado en línea: 04 feb 2017

Páginas: 249 - 255

DOI: https://doi.org/10.5372/1905-7415.0502.032

Palabras claveAntiviral therapy, drug resistance, genotype, HIV-1, in-house assay

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Palabras clave
Antiviral therapy, drug resistance, genotype, HIV-1, in-house assay